Pre_GI: SWBIT SVG BLASTN

Query: NC_010572:4585500 Streptomyces griseus subsp. griseus NBRC 13350, complete genome

Lineage: Streptomyces griseus; Streptomyces; Streptomycetaceae; Actinomycetales; Actinobacteria; Bacteria

General Information: Soil bacterium producing an antituberculosis agent. The characteristic earthy smell of freshly plowed soil is actually attributed to the aromatic terpenoid geosmin produced by species of Streptomyces. There are currently 364 known species of this genus, many of which are the most important industrial producers of antibiotics and other secondary metabolites of antibacterial, antifungal, antiviral, and antitumor nature, as well as immunosuppressants, antihypercholesterolemics, etc. Streptomycetes are crucial in the soil environment because their diverse metabolism allows them to degrade the insoluble remains of other organisms, including recalcitrant compounds such as lignocelluloses and chitin. Streptomycetes produce both substrate and aerial mycelium. The latter shows characteristic modes of branching, and in the course of the streptomycete complex life cycle, these hyphae are partly transformed into chains of spores, which are often called conidia or arthrospores. An important feature in Streptomyces is the presence of type-I peptidoglycan in the cell walls that contains characteristic interpeptide glycine bridges. Another remarkable trait of streptomycetes is that they contain very large (~8 million base pairs which is about twice the size of most bacterial genomes) linear chromosomes with distinct telomeres. These rearrangements consist of the deletion of several hundred kilobases, often associated with the amplification of an adjacent sequence, and lead to metabolic diversity within the Streptomyces group. Sequencing of several strains of Streptomyces is aimed partly on understanding the mechanisms involved in these diversification processes.

- Sequence; - BLASTN hit (Low score = Light, High score = Dark)
- hypothetical protein; - cds: hover for description

BLASTN Alignment.txt

Subject: NC_009089:4140764 Clostridium difficile 630, complete genome

Lineage: Peptoclostridium difficile; Peptoclostridium; Peptostreptococcaceae; Clostridiales; Firmicutes; Bacteria

General Information: This strain is the epidemic type X variant that has been extensively studied in research and clinical laboratories. It produces both toxin A, and B. Causative agent of pseudomembranous colitis. This genus comprises about 150 metabolically diverse species of anaerobes that are ubiquitous in virtually all anoxic habitats where organic compounds are present, including soils, aquatic sediments and the intestinal tracts of animals and humans. This shape is attributed to the presence of endospores that develop under conditions unfavorable for vegetative growth and distend single cells terminally or sub-terminally. Spores germinate under conditions favorable for vegetative growth, such as anaerobiosis and presence of organic substrates. It is believed that present day Mollicutes (Eubacteria) have evolved regressively (i.e., by genome reduction) from gram-positive clostridia-like ancestors with a low GC content in DNA. Some species are capable of producing organic solvents (acetone, ethanol, etc,), molecular hydrogen and other useful compounds. This species is now recognized as the major causative agent of pseudomembranous colitis (inflammation of the colon) and diarrhea that may occur following antibiotic treatment. This bacterium causes a wide spectrum of disease, ranging from mild, self-limiting diarrhea to serious diarrhea and, in some cases, complications such as pseudomembrane formation, toxic megacolon (dilation of the colon) and peritonitis, which often lead to lethality among patients. The bacteria produce high molecular mass polypeptide cytotoxins, A and B. Some strains produce only one of the toxins, others produce both. Toxin A causes inflammatory reaction involving hypersecretion of fluid and hemorrhagic necrosis through triggering cytokine release by neutrophils. Alteration of intestinal microbial balance with antibiotic therapy and increased exposure to the bacterium in a hospital setting allows C. difficile to colonize susceptible individuals. Moreover, it has been shown that subinhibitory concentrations of antibiotics promote increased toxin production by C. difficile.